179 related articles for article (PubMed ID: 8604347)
1. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation.
Hall SR; Campbell LE; Meek DW
Nucleic Acids Res; 1996 Mar; 24(6):1119-26. PubMed ID: 8604347
[TBL] [Abstract][Full Text] [Related]
2. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.
Fiscella M; Zambrano N; Ullrich SJ; Unger T; Lin D; Cho B; Mercer WE; Anderson CW; Appella E
Oncogene; 1994 Nov; 9(11):3249-57. PubMed ID: 7936649
[TBL] [Abstract][Full Text] [Related]
3. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein.
Maiyar AC; Phu PT; Huang AJ; Firestone GL
Mol Endocrinol; 1997 Mar; 11(3):312-29. PubMed ID: 9058378
[TBL] [Abstract][Full Text] [Related]
4. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2.
Dumaz N; Meek DW
EMBO J; 1999 Dec; 18(24):7002-10. PubMed ID: 10601022
[TBL] [Abstract][Full Text] [Related]
5. Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53.
Milne DM; Palmer RH; Meek DW
Nucleic Acids Res; 1992 Nov; 20(21):5565-70. PubMed ID: 1454521
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable.
McKendrick L; Milne D; Meek D
Mol Cell Biochem; 1999 Jan; 191(1-2):187-99. PubMed ID: 10094408
[TBL] [Abstract][Full Text] [Related]
7. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
8. Regulation of p53 mediated transactivation by the beta-subunit of protein kinase CK2.
Schuster N; Prowald A; Schneider E; Scheidtmann KH; Montenarh M
FEBS Lett; 1999 Mar; 447(2-3):160-6. PubMed ID: 10214938
[TBL] [Abstract][Full Text] [Related]
9. Protein p53 modulates transcription from a promoter containing its binding site in a concentration-dependent manner.
Kristjuhan A; Maimets T
Eur J Biochem; 1995 Dec; 234(3):827-31. PubMed ID: 8575441
[TBL] [Abstract][Full Text] [Related]
10. Specific DNA binding by p53 is independent of mutation at serine 389, the casein kinase II site.
Rolley N; Milner J
Oncogene; 1994 Oct; 9(10):3067-70. PubMed ID: 8084615
[TBL] [Abstract][Full Text] [Related]
11. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site.
Blaydes JP; Hupp TR
Oncogene; 1998 Aug; 17(8):1045-52. PubMed ID: 9747884
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53.
Sugikawa E; Yazaki N; Tsunoda S; Nakanishi N; Ohashi M
Biochem Biophys Res Commun; 1999 Aug; 261(2):256-63. PubMed ID: 10425175
[TBL] [Abstract][Full Text] [Related]
13. Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation.
Preuss U; Kreutzfeld R; Scheidtmann KH
Int J Cancer; 2000 Oct; 88(2):162-71. PubMed ID: 11004663
[TBL] [Abstract][Full Text] [Related]
14. Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II.
Bousset K; Oelgeschläger MH; Henriksson M; Schreek S; Burkhardt H; Litchfield DW; Lüscher-Firzlaff JM; Lüscher B
Cell Mol Biol Res; 1994; 40(5-6):501-11. PubMed ID: 7735324
[TBL] [Abstract][Full Text] [Related]
15. A novel system to investigate the phosphorylation of the p53 tumor suppressor protein by the protein kinase CK2.
McKendrick L; Meek DW
Cell Mol Biol Res; 1994; 40(5-6):555-61. PubMed ID: 7735330
[TBL] [Abstract][Full Text] [Related]
16. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
[TBL] [Abstract][Full Text] [Related]
17. Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA binding and is a target for casein kinase II phosphorylation.
Kolman JL; Taylor N; Marshak DR; Miller G
Proc Natl Acad Sci U S A; 1993 Nov; 90(21):10115-9. PubMed ID: 8234266
[TBL] [Abstract][Full Text] [Related]
18. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo.
Jamal S; Ziff EB
Oncogene; 1995 Jun; 10(11):2095-101. PubMed ID: 7784054
[TBL] [Abstract][Full Text] [Related]
19. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
Di Stefano V; Soddu S; Sacchi A; D'Orazi G
Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
[TBL] [Abstract][Full Text] [Related]
20. A single serine residue at position 375 of VP16 is critical for complex assembly with Oct-1 and HCF and is a target of phosphorylation by casein kinase II.
O'Reilly D; Hanscombe O; O'Hare P
EMBO J; 1997 May; 16(9):2420-30. PubMed ID: 9171355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
